IP50-01: Comparative Effectiveness of Gemcitabine Intravesical System vs Real-World Intravesical Chemotherapy in BCG-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer with Carcinoma in Situ: An Indirect Treatment Comparison Using an External Contr

IP50-01: Comparative Effectiveness of Gemcitabine Intravesical System vs Real-World Intravesical Chemotherapy in BCG-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer with Carcinoma in Situ: An Indirect Treatment Comparison Using an External Contr

Sunday, May 17, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)

146A

Abstract

Speakers

Girish Kulkarni

Girish Kulkarni

Professor, Division of Urology, Department of SurgeryUniversity of Toronto

Sessions

IP50: Bladder Cancer: Non-invasive IV

Sunday, May 17, 2026 7:00 AM to 9:00 AM

Christopher Anderson · Columbia University Medical Center

William Tabayoyong · Department of Urology

Mary Westerman · Department of Urology, University of North Carolina

Registered attendees

Mitchell Goldenberg

Mitchell Goldenberg

Clinical Fellow, FPMRSUniversity of Southern California

Scott Flanders

VP of Medical AffairsImmunityBio, Inc.

Log in

See all the content and easy-to-use features by logging in or registering!